One of the world’s biggest genetic databases comprises DNA data donated over the years by more than a million retired ...

On Thursday’s episode of Mad Money, host Jim Cramer turned his focus to large-cap stocks that surged by $10 or more in a single day.

As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity ...

More than 40% of Americans are obese, according to the Centers for Disease Control and Prevention (CDC). And the epidemic isn ...

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...

Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

A new study has found that older adults and women taking the weight-loss drug semaglutide may lose more muscle than others, ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

With their lengthening laundry list of health benefits, drugs like Ozempic are showing promise for people who struggle with addiction.

Newsweek spoke to some experts about whether the weight loss drug could have an impact on birth rates in America.